-
Thirty-one percent of telaprevir patients who had gotten no benefit at all from previous treatments with the current hepatitis C regimen, a combination of interferon and antiviral drug ribavirin, had SVRs.
FORBES: Vertex Maintains Lead Over Merck In Hepatitis C
-
Many eye-vitamin formulations currently on the market are based on research conducted by the National Institutes of Health in a project called Age-Related Eye Disease Study, or AREDS. The first phase of the clinical trial, completed in 2001, found that a specific combination of vitamins C and E, along with beta-carotene and zinc, reduced the risk of age-related macular degeneration by as much as 25%.
WSJ: The Crucial Years for Protecting Your Eye Health
-
An advisory panel to the U.S. Food and Drug Administration unanimously voted Nov. 14 that Roche's new combination therapy for hepatitis C should be approved.
FORBES: Roche And Schering's Desperate Duel